The use of liposomal anthracycline analogues for childhood malignancies: A systematic review

Sieswerda, Elske; Kremer, Leontien C. M.; Caron, Huib N.; Dalen, Elvira C. van

doi:10.1016/j.ejca.2011.03.024

Cited by 23 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis of 2 other randomized controlled trials in women with metastatic breast cancer found fewer clinical and subclinical cardiac events in the group receiving liposomal anthracyclines [46]. However, no randomized controlled trials in children have been conducted to reproduce these results [51]. …”

Section: Preventing Cardiotoxicitymentioning

confidence: 99%

“…Pegylated anthracyclines, compared to regular anthracyclines, have longer circulation times, longer half-lives, slower clearance from plasma, a smaller volume of distribution and they cannot penetrate cardiac cell tight junctions [50,51]. These characteristics result in higher drug concentrations in tumors and lower concentrations in the heart [51].…”

Section: Preventing Cardiotoxicitymentioning

confidence: 99%

“…These characteristics result in higher drug concentrations in tumors and lower concentrations in the heart [51]. Therefore, pegylated anthracyclines decrease cardiotoxicity while maintaining oncological efficacy.…”

Section: Preventing Cardiotoxicitymentioning

confidence: 99%

See 2 more Smart Citations

Cardiotoxicity and Cardioprotection in Childhood Cancer

Lipshultz¹,

Sambatakos

Maguire

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

Children diagnosed with cancer are now living longer as a result of advances in treatment. However, some commonly used anticancer drugs, although effective in curing cancer, can also cause adverse late effects. The cardiotoxic effects of anthracycline chemotherapy, such as doxorubicin, and radiation can cause persistent and progressive cardiovascular damage, emphasizing a need for effective prevention and treatment to reduce or avoid cardiotoxicity. Examples of risk factors for cardiotoxicity in children include higher anthracycline cumulative dose, higher dose of radiation, younger age at diagnosis, female sex, trisomy 21 and black race. However, not all who are exposed to toxic treatments experience cardiotoxicity, suggesting the possibility of a genetic predisposition. Cardioprotective strategies under investigation include the use of dexrazoxane, which provides short- and long-term cardioprotection in children treated with doxorubicin without interfering with oncological efficacy, the use of less toxic anthracycline derivatives and nutritional supplements. Evidence-based monitoring and screening are needed to identify early signs of cardiotoxicity that have been validated as surrogates of subsequent clinically significant cardiovascular disease before the occurrence of cardiac damage, in patients who may be at higher risk.

show abstract

Section: Preventing Cardiotoxicitymentioning

confidence: 99%

Section: Preventing Cardiotoxicitymentioning

confidence: 99%

See 1 more Smart Citation

Cardiotoxicity and Cardioprotection in Childhood Cancer

Lipshultz¹,

Sambatakos

Maguire

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…In children with cancer, several observational studies described the use of liposomal ANTs, but no randomized controlled trials have been reported. Hence, definite data on cardiac safety of these formulations need longer follow-up of both cardiotoxic effects as well as the anticancer response (237). Of note, liposomal ANTs also have specific side-effects, such as allergic reactions and hand-foot syndrome, a dermatologic toxic reaction that can lead to considerable discomfort (82).…”

Section: Strategies For Cardiotoxicity Preventionmentioning

confidence: 99%

Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

Štěrba

Popelová

Vávrová

et al. 2013

Antioxidants & Redox Signaling

284

192

View full text Add to dashboard Cite

“…Despite the availability of several formulations (i.e. liposomal DOX, pegylated liposomal DOX and liposomal daunorubicin), their cost and the lack of randomized trials in children with cancer [19], restricts their use to limited oncologic settings [20]. Another strategy is to utilize less cardiotoxic anthracycline derivatives, such as epirubicin or idarubicin, although their better safety profile is yet to be proven [21,22].…”

Section: Cardioprotective Strategiesmentioning

confidence: 99%

Doxorubicin cardiotoxicity and target cells: a broader perspective

et al. 2016

View full text Add to dashboard Cite

The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication makes difficult to design successful preventive or curative measures. Although cardiomyocyte has been considered a classical cellular target, other cells including various types of undifferentiated cells are involved in myocardial homeostasis. Such perspective may shed light on previously unrecognized aspects of cardiotoxicity and promote new experimental and clinical cardioprotective strategies. In this review, different cellular targets of doxorubicin are discussed with the focus on cardiac progenitor cells, oxidative stress, DNA damage, senescence and apoptosis all of which contribute to their compromised functional properties.

show abstract

The use of liposomal anthracycline analogues for childhood malignancies: A systematic review

Cited by 23 publications

References 26 publications

Cardiotoxicity and Cardioprotection in Childhood Cancer

Cardiotoxicity and Cardioprotection in Childhood Cancer

Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

Doxorubicin cardiotoxicity and target cells: a broader perspective

Contact Info

Product

Resources

About